Core revenue for 2025 totaled $29.6 million compared with $32.5 million in 2024, a 9% decline. In the fourth quarter, core revenue was $6.8 million compared with $8.6 million in the prior-year quarter, down 22%.For the full year ended Dec. 31, 2025, MaxCyte reported total revenue of $33.0 million, down from $38.6 million in 2024, a 15% decline. Fourth-quarter total revenue was $7.3 million versus $8.7 million a year earlier, down 16%.MaxCyte (NASDAQ:MXCT) executives told investors the company made “meaningf ...